Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Frontiers in Cellular and Infection Microbiology|August 25, 2012
Characterization of the mechanism of protection mediated by CS-D7, a monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB)Gregory Pancari, Hongxia Fan, Sharon Smith, et al.
Current Drug Metabolism|April 6, 2012
Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancerDan Lu, Howard A Burris, Bei Wang, et al.
Clinical Pharmacology and Therapeutics|December 31, 2025
Bridging the Gap: Integrating Quantitative Systems Pharmacology and Pharmacometrics in Drug DevelopmentGeorgi I Kapitanov, Justin C Earp, Kapil Gadkar, et al.
Clinical and Translational Science|August 25, 2021
Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)Benjamin Wu, Nitzan Sternheim, Priya Agarwal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2018
A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor KineticsLaurent Claret, Jin Y Jin, Charles Ferté, et al.
Clinical Pharmacokinetics|January 20, 2012
A guide to rational dosing of monoclonal antibodiesShuang Bai, Karin Jorga, Yan Xin, et al.
Pharmaceutical Research|June 19, 2012
Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humansYan Xin, Shuang Bai, Lisa A Damico-Beyer, et al.
Pediatrics|November 24, 2017
4-Valent Human Papillomavirus (4vHPV) Vaccine in Preadolescents and Adolescents After 10 YearsDaron G Ferris, Rudiwilai Samakoses, Stanley L Block, et al.
The AAPS Journal|June 2, 2011
AAPS workshop report: strategies to address therapeutic protein-drug interactions during clinical developmentSandhya Girish, Steven W Martin, Mark C Peterson, et al.
Cancer Chemotherapy and Pharmacology|October 13, 2017
Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxaneChunze Li, Bei Wang, Shang-Chiung Chen, et al.
Pageof 9